This Is Too Hot For Verona Pharma Plc ADR (NASDAQ: VRNA), Let’s Take A Closer Look

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, VRNA falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Verona Pharma Plc ADR is $2.65B. A total of 1.06 million shares were traded on the day, compared to an average of 1.17M shares.

In the most recent transaction, ZACCARDELLI DAVID sold 600,000 shares of VRNA for 3.76 per share on Sep 11 ’24. After the transaction, the President and CEO now owns 15,250,704 company shares. In a previous transaction on Sep 11 ’24, Hahn Mark W sold 600,000 shares at 3.76 per share. VRNA shares that Chief Financial Officer owns now total 14,339,688.

Among the insiders who bought shares, MARK HAHN acquired of 75,000 shares on Sep 11 ’24 at a per-share price of $28.04. In another insider transaction, DAVID ZACCARDELLI bought 75,000 shares at $28.04 per share on Sep 11 ’24.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, VRNA has a high of $32.88 and a low of $11.39.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $2.08, while its Total Shareholder’s Equity was $148.00M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 5.00.

Most Popular

Related Posts